Search results for " Muscarinic"

showing 10 items of 101 documents

Heat shock protein (Hsp) regulation by muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus.

2018

The cholinergic system plays a crucial role in modulating in the central nervous system physiological responses such as neurogenesis, neuronal differentiation, synaptic plasticity, and neuroprotection. In a recent study, we showed that Oxotremorine-M, a non-selective muscarinic acetylcholine receptor agonist, is able to transactivate the fibroblast growth factor receptor and to produce a significant increase in the hippocampal primary neurite outgrowth. In the present study we aimed to explore in the rat hippocampus the possible effect of acute or chronic treatment with Oxotremorine-M on some heat shock proteins (Hsp60, Hsp70, Hsp90) and on activation of related transcription factor heat sh…

0301 basic medicineAgonistMalemedicine.medical_specialtymedicine.drug_classPhysiologyClinical BiochemistryNeuronal OutgrowthScopolamineheat shock proteinHsp90NeuroprotectionHippocampusHsp7003 medical and health sciencesmuscarinic receptor0302 clinical medicineHeat Shock Transcription FactorsHeat shock proteinInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineAnimalsRats WistarHSF1Heat-Shock ProteinsNeuronsNeuronal PlasticityChemistryOxotremorineNeurodegenerative DiseasesCell BiologyReceptors Fibroblast Growth FactorReceptors MuscarinicHsp70Rats030104 developmental biologyEndocrinologyheat shock factor 1HSP60030217 neurology & neurosurgerymedicine.drugSignal TransductionJournal of cellular physiology
researchProduct

Synergistic action of CB1 and 5-HT2B receptors in preventing pilocarpine-induced status epilepticus in rats

2019

Abstract Endocannabinoids (eCBs) and serotonin (5-HT) play a neuromodulatory role in the central nervous system. Both eCBs and 5-HT regulate neuronal excitability and their pharmacological potentiation has been shown to control seizures in pre-clinical and human studies. Compelling evidence indicates that eCB and 5-HT systems interact to modulate several physiological and pathological brain functions, such as food intake, pain, drug addiction, depression, and anxiety. Nevertheless, there is no evidence of an eCB/5-HT interaction in experimental and human epilepsies, including status epilepticus (SE). Here, we performed video-EEG recording in behaving rats treated with the pro-convulsant age…

0301 basic medicineMaleCannabinoid receptormedicine.medical_treatmentPharmacologySettore BIO/09 - Fisiologia0302 clinical medicineStatus Epilepticus5-HT2BEEGStatus epilepticuPilocarpineCalcium Channel BlockersEndocannabinoid systemCB1Clinical applicationNeurologyPilocarpinemedicine.symptommedicine.drugReceptorAM251AgonistSerotoninEndocannabinoid systemmedicine.drug_classMorpholinesCannabinoid receptors; Clinical applications; EEG; Endocannabinoid system; Serotonin; Status epilepticus; Synergistic interactions; Animals; Benzoxazines; Calcium Channel Blockers; Male; Morpholines; Muscarinic Agonists; Naphthalenes; Pilocarpine; Rats; Rats Sprague-Dawley; Receptor Cannabinoid CB1; Receptor Serotonin 5-HT2B; Serotonin 5-HT2 Receptor Agonists; Status EpilepticusStatus epilepticusClinical applicationsMuscarinic AgonistsNaphthaleneslcsh:RC321-57103 medical and health sciencesmedicineAnimalsCannabinoid receptorslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryCannabinoidbusiness.industryAntagonistSynergistic interactionsBenzoxazinesRats030104 developmental biologySerotoninCannabinoidSprague-Dawleybusiness030217 neurology & neurosurgerySerotonin 5-HT2 Receptor Agonists
researchProduct

Non-neuronal acetylcholine involved in reproduction in mammals and honeybees.

2017

Bacteria and archaea synthesize acetylcholine (ACh). Thus, it can be postulated that ACh was created by nature roughly three billion years ago. Therefore, the wide expression of ACh in nature (i.e., in bacteria, archaea, unicellular organisms, plants, fungi, non-vertebrates and vertebrates and in the abundance of non-neuronal cells of mammals) is not surprising. The term non-neuronal ACh and non-neuronal cholinergic system have been introduced to describe the auto- and paracrine, that is, local regulatory actions of ACh in cells not innervated by neuronal cholinergic fibers and to communicate among themselves. In this way non-neuronal ACh binds to the nicotinic or muscarinic receptors expre…

0301 basic medicineMammalsInsecticidesNicotineCholinergic FibersBiologyBiochemistryEmbryonic stem cellReceptors MuscarinicAcetylcholineCell biology03 medical and health sciencesCellular and Molecular NeuroscienceParacrine signalling030104 developmental biologyNicotinic agonistCell MovementMuscarinic acetylcholine receptormedicineOviductAnimalsHumansAcetylcholineFunction (biology)medicine.drugJournal of neurochemistry
researchProduct

Modulation of Hippocampal Circuits by Muscarinic and Nicotinic Receptors

2017

This article provides a review of the effects of activation of muscarinic and nicotinic receptors on the physiological properties of circuits in the hippocampal formation. Previous articles have described detailed computational hypotheses about the role of cholinergic neuromodulation in enhancing the dynamics for encoding in cortical structures and the role of reduced cholinergic modulation in allowing consolidation of previously encoded information. This article will focus on addressing the broad scope of different modulatory effects observed within hippocampal circuits, highlighting the heterogeneity of cholinergic modulation in terms of the physiological effects of activation of muscarin…

0301 basic medicinevolume transmissioncholinergic fibersCognitive NeuroscienceNeuroscience (miscellaneous)ReviewHippocampal formationReceptors NicotinicCholinergic modulationHippocampuslcsh:RC321-571tonic depolarization03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineNeuromodulationMuscarinic acetylcholine receptorNeural PathwaysmedicineAnimalsHumanslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryCholinergic FibersNicotinic ReceptorsChemistrypresynaptic inhibitionReceptors MuscarinicacetylcholineSensory Systems030104 developmental biologymedicine.anatomical_structureCholinergicNeuroscience030217 neurology & neurosurgeryAcetylcholinemedicine.drugNeuroscienceFrontiers in Neural Circuits
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell’Apparato Respiratorio, AOU Maggiore della Carità, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences “V Tiberio”, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2 ) with nicotine addiction

2009

Genetic factors contribute to the overall risk of developing nicotine addiction, which is the major cause of preventable deaths in western countries. However, knowledge regarding specific polymorphisms influencing smoking phenotypes remains scarce. In the present study we provide evidence that a common single nucleotide polymorphism (SNP) in the 5′ untranslated region of CHRM2, the gene coding for the muscarinic acetylcholine receptor 2 is associated with nicotine addiction. CHRM2 was defined as a candidate gene for nicotine addiction based on previous evidence that linked variations in CHRM2 to alcohol and drug dependence. A total of more than 5,500 subjects representative of the German po…

AdultMaleNicotineCandidate geneAdolescentmedia_common.quotation_subjectSingle-nucleotide polymorphismBiologyBioinformaticsNicotineCellular and Molecular NeuroscienceMuscarinic acetylcholine receptormedicineHumansSNPGenetic Predisposition to DiseaseAlleleAllelesGenetics (clinical)Agedmedia_commonAged 80 and overGeneticsReceptor Muscarinic M2AddictionSmokingGenetic VariationTobacco Use DisorderOdds ratioMiddle AgedPsychiatry and Mental healthFemalemedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Blockade of nicotinic and muscarinic receptors facilitates spontaneous migration of human peripheral granulocytes: failure in cystic fibrosis.

2012

Circulating leucocytes express muscarinic (m) and nicotinic (n) receptors and synthesize acetylcholine (ACh) regulating various cell functions. Leucocytes from patients with cystic fibrosis contain less ACh; therefore it was tested whether the regulation of cellular functions like migration differed from healthy volunteers.Peripheral blood (10-20 ml) was used, leucocytes were isolated by Ficoll® gradient and the commercial MIGRATEST® combined with flow cytometric analysis was applied (pore size 3 μm).In the absence of test substances 4900±1800 (n=10) leucocytes migrated within a time period of 2 h. In the presence of tubocurarine (TC, 30 μM) the cell number increased to 7500±2700 [n=10] cor…

AdultMalemedicine.medical_specialtyAdolescentCystic FibrosisBiologyReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyCholinergic AntagonistsYoung AdultCell Migration Assays LeukocyteCell MovementInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4HumansGeneral Pharmacology Toxicology and PharmaceuticsReceptorChildMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineReceptors MuscarinicNicotinic agonistEndocrinologyCholinergicFemaleAcetylcholinemedicine.drugGranulocytesLife sciences
researchProduct

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

2005

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein …

AgonistReceptors Neuropeptidemedicine.drug_classG proteinBiologyKidneyBiochemistryCell LineReceptors G-Protein-CoupledGTP-binding protein regulatorsGTP-Binding ProteinsOrexin ReceptorsTransduction GeneticMuscarinic acetylcholine receptormedicineCyclic AMPHumansCalcium SignalingPharmacologyReceptor Muscarinic M3Neurotransmitter AgentsOrexinsDose-Response Relationship DrugNeuropeptidesIntracellular Signaling Peptides and ProteinsMuscarinic acetylcholine receptor M3Fusion proteinOrexin receptorCell biologyBiochemistryCalciumSignal transductionBaculoviridaeSignal TransductionBiochemical pharmacology
researchProduct

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

2003

Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human alpha 3 beta 4, alpha 4 beta 2, and alpha 6 beta 4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric alpha 7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype. Galantamine potentiates agonist responses of the four nAChR subtypes studied in the same window of concentrations (i.e., 0.1-1 microM), which correlates with the cerebrospinal fluid concentration of the drug at the recommended daily dosage of 16 to 24 mg. At concentrations10 microM, gal…

Agonistmedicine.medical_specialtymedicine.drug_classRecombinant Fusion ProteinsAllosteric regulationPhenylcarbamatesRivastigminePharmacologyReceptors NicotinicMiceAllosteric RegulationPiperidinesInternal medicineMuscarinic acetylcholine receptormedicineGalantamineAnimalsHumansDonepezilReceptorTrichlorfonCells CulturedPharmacologyNeuronsChemistryGalantamineLigand (biochemistry)Receptors MuscarinicEndocrinologyNicotinic agonistIndansTacrineMolecular MedicineCholinergicCarbamatesCholinesterase Inhibitorsmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct